Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study is designed as a Phase III, multicenter trial, comparing progression-free survival
(PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus
BEAM transplant regimen versus a regimen adding Bexxar to BEAM.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI)